| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1998;66:1909-1914
© 1998 The Society of Thoracic Surgeons
a Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
b Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
c Department of Radiation Oncology,, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
d Department of Biostatistics and Epidemiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
e Department of Anatomic Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Address reprint requests to Dr Rice, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
e-mail: (ricet{at}cesmtp.ccf.org)
Presented at the Poster Session of the Thirty-fourth Annual Meeting of The Society of Thoracic Surgeons, New Orleans, LA, Jan 26–28, 1998.
Background. This study assessed toxicity, tumor response, disease control, and survival after short-course induction chemoradiotherapy and surgical resection in patients with stage III non-small-cell lung carcinoma.
Methods. Forty-five patients with stage III non-small-cell lung carcinoma received 12-day induction therapy of a 96-hour continuous infusion of cisplatin (20 mg/m2 per day), 24-hour infusion of paclitaxel (175 mg/m2), and concurrent accelerated fractionation radiation therapy (1.5 Gy twice daily) to a dose of 30 Gy. Surgical resection was scheduled for 4 weeks later. Postoperatively, a second identical course of chemotherapy and concurrent radiation therapy (30 to 33 Gy) was given.
Results. Induction toxicity resulted in hospitalization of 18 (40%) patients for neutropenic fever. No induction deaths occurred. Of 40 (89%) patients who underwent thoracotomy, resection for cure was possible in 32 (71%) patients. Pathologic response was noted in 21 (47%) patients, and 14 (31%) were downstaged to mediastinal node negative (stage 0, I, or II). At a median follow-up of 19 months, 24 patients were alive, 10 with recurrent disease. Of 21 deaths, 16 were from recurrent disease, three were from treatment, and two were unrelated. Recurrent disease was distant in 21 patients, distant and locoregional in 2, and locoregional in 3. The Kaplan-Meier projected 24-month survival is 49%. Projected 24-month survival is 61% for stage IIIA, 17% for stage IIIB (p = 0.035); 84% for pathologic responders, 22% for nonresponders (p < 0.001); 83% for downstaged patients (stage 0, I, or II), 33% for those not downstaged (p = 0.005); and 63% for resectable patients, 14% for unresectable patients (p = 0.007).
Conclusions. We conclude that short-course neoadjuvant therapy with paclitaxel (1) has manageable toxicity and a low treatment mortality, (2) results in good tumor response and downstaging, (3) provides excellent locoregional control with most recurrences being distant, and (4) has improved the median survival compared with historical controls. Survival was better in stage IIIA patients, resectable patients, pathologic responders, and patients downstaged to mediastinal node negative disease (stage 0, I, or II).
Related Article
Ann. Thorac. Surg. 1998 66: 1914.
This article has been cited by other articles:
|
|
 |
|
  H.-x. Yang, X. Hou, P. Lin, T.-h. Rong, H. Yang, and J.-h. Fu Survival and risk factors of surgically treated mediastinal invasion T4 non-small cell lung cancer. Ann. Thorac. Surg., August 1, 2009; 88(2): 372 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Pottgen, S. Levegrun, D. Theegarten, S. Marnitz, S. Grehl, R. Pink, W. Eberhardt, G. Stamatis, T. Gauler, G. Antoch, et al. Value of 18F-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography/Computed Tomography in Non-Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy Clin. Cancer Res., January 1, 2006; 12(1): 97 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. DeCamp, T. W. Rice, D. J. Adelstein, M. A. Chidel, L. A. Rybicki, S. C. Murthy, and E. H. Blackstone Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer J. Thorac. Cardiovasc. Surg., July 1, 2003; 126(1): 17 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. Evans and T. J. Lynch Jr. Lung Cancer Oncologist, October 1, 2001; 6(5): 407 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mateu-Navarro, R. Rami-Porta, R. Bastus-Piulats, L. Cirera-Nogueras, and G. Gonzalez-Pont Remediastinoscopy after induction chemotherapy in non-small cell lung cancer Ann. Thorac. Surg., August 1, 2000; 70(2): 391 - 395. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
